title: Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck.
abstract: BACKGROUND
  Since head and neck squamous cell carcinoma (HNSCC) preferentially metastasizes to the locoregional lymphatics, treatment of the tumor-draining cervical lymph nodes is paramount.
  
  
  RESULTS
  We developed a hyaluronan-cisplatin (HA-Pt) nanoconjugate with prolonged lymphatic retention and greatly improved tumor tissue deposition for the treatment of metastatic HNSCC. We also developed an orthotopic metastatic xenograft model of HNSCC to examine the efficacy of the nanoconjugate. HNSCC (1/week x 3 weeks) were completely cured for 57% of the female mice in the HA-Pt treatment group, which demonstrated greatly hindered HNSCC progression compared with the standard cisplatin therapy (p < 0.05).
  
  
  CONCLUSIONS
  With this insight, we will be able to optimize the carriers for better uptake, penetration and retention within cancer cells.
authors.affiliation: Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA.
authors.forename: Shuang
authors.initials: S
authors.lastname: Cai
authors.forename: Yumei
authors.initials: Y
authors.lastname: Xie
authors.forename: Neal M
authors.initials: NM
authors.lastname: Davies
authors.forename: Mark S
authors.initials: MS
authors.lastname: Cohen
authors.forename: M Laird
authors.initials: ML
authors.lastname: Forrest
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical; D002945:Cisplatin / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D018450:Disease Progression; D004337:Drug Carriers; D005240:Feasibility Studies; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry* / Q000633:toxicity; D008207:Lymphatic Metastasis; D008208:Lymphatic System / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D013997:Time Factors; D014018:Tissue Distribution; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D006820:Hyaluronic Acid; D002945:Cisplatin